Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Eli Lilly to supply 400,000 tablets of its COVID-19 treatment to India

05/04/2021 | 07:27am EDT
FILE PHOTO: An Eli Lilly and Co pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey

(Reuters) - Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to the Indian government as the country fights a raging pandemic that has morgues and hospitals overflowing.

With 3.45 million active cases, India recorded 357,229 new infections over the last 24 hours, while deaths rose 3,449 for a toll of 222,408, health ministry data showed. Experts say actual numbers could be five to 10 times higher, however.

The drugmaker said it will work urgently to increase the supply multifold over the coming weeks.

On Monday, India's drug regulator gave emergency use approval to Lilly's treatment, baricitinib, for its use in hospitalized COVID-19 patients requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.

The drug will be used in combination with Gilead Sciences's COVID-19 drug remdesivir.

Lilly is offering donations of its rheumatoid arthritis drug baricitinib for COVID-19 treatment to the Indian government through aid organization Direct Relief.

(Reporting by Dania Nadeem in Bengaluru; Editing by Shinjini Ganguli)


ę Reuters 2021
All news about GILEAD SCIENCES, INC.
04:07pGILEAD SCIENCESá : to Present at Upcoming Investor Conferences
BU
03:06pGILEAD SCIENCES INCá : Submission of Matters to a Vote of Security Holders (form..
AQ
05/10GILEAD SCIENCESá : Egypt's Eva Pharma to export COVID-19 drug remdesivir to Indi..
RE
05/06GILEAD SCIENCESá : Significant Insider Selling in Shares of Gilead Sciences (GIL..
MT
05/06GILEAD SCIENCESá : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
05/06GILEAD SCIENCESá : to Present at Upcoming Investor Conferences
BU
05/06GILEAD SCIENCES, INC.á : SEC Filing 10Q-1
CO
05/05EVEREST MEDICINES'á : Breast Cancer Therapy Wins Orphan Drug Designation in Sout..
MT
05/05INSIDER TRENDS : Gilead Sciences Sees 90 Days of Insider Buying Trend Reducing w..
MT
05/04GILEAD SCIENCESá : Eli Lilly to supply 400,000 tablets of its COVID-19 treatment..
RE
More news
Financials (USD)
Sales 2021 24 685 M - -
Net income 2021 6 913 M - -
Net Debt 2021 21 984 M - -
P/E ratio 2021 13,0x
Yield 2021 4,10%
Capitalization 85 949 M 85 949 M -
EV / Sales 2021 4,37x
EV / Sales 2022 4,28x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 74,96 $
Last Close Price 68,53 $
Spread / Highest target 45,9%
Spread / Average Target 9,38%
Spread / Lowest Target -12,4%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Richard J. Whitley Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.18.28%86 425
WUXI APPTEC CO., LTD.13.72%57 982
VERTEX PHARMACEUTICALS-8.15%55 488
REGENERON PHARMACEUTICALS7.05%53 556
BIONTECH SE136.47%43 665
BEIGENE, LTD.23.69%28 345